Gilbert G. et al. (Nov. 2000) “Four hydrophobic amino acids of the factor VIII C2 domain contribute to the membrane binding motif” Blood 96(11):633a. |
Healey J.F. et al. (1998) Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII Blood 92:3701-3709. |
Jacquemin, M.G. et al. (1998) “Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor” Blood 92:496-506. |
Kim, S.W. et al. (2000) “Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis” Biochemistry 39:1951-1958. |
Lin, S.W. et al. (Dec. 1993) “Characterization of Genomic Defects of hemophilia A in patients of Chinese origin” Genomics 18(3):496-504. |
Lind, P. et al. (1995) “Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization” Eur. J. Biochem. 232:19-27. |
Macedo-Ribeiro, S. et al., (1999) “Crystal structures of the membrane-binding C2 domain of human coagulation factor V” Nature 402:434-439. |
Ortel T.L. et al., (1998) “Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations” Blood 91:4188-4196. |
Ortel, T.L. et al. (1994) “Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras” J. Biol. Chem. 269:15898-15905. |
Pratt K.P. (1999) “Structure of the C2 domain of human factor VIII at 1.5 Å resolution” Nature 402:439-442. |
Prescott, R. et al. (1997) “The inhibitory antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with fVIII autoantibodies” Blood 89:3663-3671. |
Sawamoto, Y. et al. (1998) “C2 domain restricted epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CSP-P, in previously treated hemophilia A patients without inhibitors” Thromb. Haemostas. 79:62-68. |
Scandella et al. (1988) Proc. Natl. Acad. Sci. USA 85:6152-6156. |
Shima, M.D. et al. (1993) “A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine” Thromb. Haemost. 69:240-246. |
Arai, M. et al. (1989) “Molecular basis of factor-VIII inhibition by human antibodies—antibodies that bind to the factor-VIII light chain prevent the interaction of factor-VIII with phospholipid” J. Clin. Invest. 83:1978-1984. |
Barrow, R. T. et al. (2000) “Reduction of the antigenicity of factor VIII toward complex inhibitory plasmas using multiply-substituted hybrid human/porcine factor VIII molecules” Blood 95:557-561. |
Barrowcliffe, T. W. et al. (1983) “Binding to phospholipid protects factor VIII from inactivation by human antibodies” J. Lab. Clin. Med. 101:34-43. |
Fulcher C.A. et al. (1985) “Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments” Proc. Natl. Acad. Sci. USA 82:7728-7732. |
Lubin, I.M. et al. (1994) “Elimination of a Major Inhibitor Epitope in Factor VIII”; J. Biol. Chem. 269:8639-8641. |